Emerging treatments in type 2 diabetes: focus on canagliflozin

References

• DanaeiGFinucaneMMLuYGlobal Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose)National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participantsLancet20113789785314021705069
   PubMed Web of Science ®Google Scholar
• BaileyCJRenal glucose reabsorption inhibitors to treat diabetesTrends Pharmacol Sci2011322637121211857
   PubMed Web of Science ®Google Scholar
• ElkinsonSScottLCanagliflozin: first global approvalDrugs201373997998823729000
   PubMed Web of Science ®Google Scholar
• TriplittCLUnderstanding the kidneys’ role in blood glucose regulationAm J Manag Care201218Suppl 1S11S1622559853
   PubMedGoogle Scholar
• INVOKANA™ [prescribing information]Titusville, NJJanssen Pharmaceuticals, Inc2013
   Google Scholar
• Committee for Medicinal Products for Human Use of the European Medicines AgencyEMA/374133/2013. Assessment report on the use of canagliflozinLondon, UKEuropean Medicines Agency2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002649/WC500156457.pdfAccessed April 2, 2014
   Google Scholar
• TurkEMartinMGWrightEMStructure of the human Na+/glucose cotransporter gene SGLT1J Biol Chem19942692115204152098195156
   PubMed Web of Science ®Google Scholar
• KanaiYLeeWSYouGBrownDHedigerMAThe human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reasbsorptive mechanism for D-glucoseJ Clin Invest19949313974048282810
   PubMed Web of Science ®Google Scholar
• DevineniDMorrowLHompeschMCanagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulinDiabetes Obes Metab201214653954522226086
   PubMed Web of Science ®Google Scholar
• ShaSDevineniDGhoshACanagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjectsDiabetes Obes Metab201113766967221457428
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals IncInvokana™ (canagliflozin) tablets for oral use: US prescribing informationTitusville, NJJanssen Pharmaceuticals, Inc2013 Available from: http://www.janssenmd.com/pdf/invokana/PI-INVOKANA.pdfAccessed September 1, 2013
   Google Scholar
• YaleJBakrisGCariouBEfficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney diseaseDiabetes Obes Metab201315546347323464594
   PubMed Web of Science ®Google Scholar
• CefaluWTLeiterLAYoonKHEfficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trialLancet2013382989694195023850055
   PubMed Web of Science ®Google Scholar
• NyirjesyPZhaoYWaysKUsiskinKEvaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitorCurr Med Res Opin20122871173117822632452
   PubMed Web of Science ®Google Scholar
• NislySKolanczykDWaltonACanagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in treatment of diabetesAm J Health Syst Pharm201370431131923370138
   PubMed Web of Science ®Google Scholar
• StenlöfKCefaluWTKimKAEfficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes Obes Metab201315437238223279307
   PubMed Web of Science ®Google Scholar
• StenlöfKCefaluWTKimKALong-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M studyCurr Med Res Opin2013154372382
   Google Scholar
• Janssen Research and Development, LLCThe CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis – Metformin and Pioglitazone) Available from: http://clinicaltrials.gov/ct2/show/NCT01106690. NLM identifier: NCT01106690Accessed September 20, 2013
   Google Scholar
• Janssen Research and Development, LLC [homepage on the Internet]First Results from Phase 3 CANVAS Trial Show Canagliflozin as Add-on Therapy to Insulin Lowered Blood Sugar Levels in Patients With Type 2 Diabetes at an Elevated Risk for Cardiovascular Disease1022012Titusville, NJJanssen Pharmaceuticals, Inc Available from: http://www.investor.jnj.com/releasedetail.cfm?releaseid=710584Accessed October 23, 2013
   Google Scholar
• Janssen Research and Development, LLCA Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise Available from: http://clinicaltrials.gov/ct2/show/NCT01809327. NLM identifier: NCT01809327Accessed September 20, 2013
   Google Scholar
• Janssen Scientific Affairs, LLCEvaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents Available from: http://clinicaltrials.gov/ct2/show/NCT01939496. NLM identifier: NCT01939496Accessed September 20, 2013
   Google Scholar
• Janssen-Cilag International NVA Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers Available from: http://clinicaltrials.gov/ct2/show/NCT01877889. NLM identifier: NCT01877889Accessed September 20, 2013
   Google Scholar
• Janssen Scientific Affairs, LLCEvaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents Available from: http://clinicaltrials.gov/ct2/show/NCT01939496. NLM identifier: NCT01939496Accessed September 20, 2013
   Google Scholar
• TaylorSHarrisKThe clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitusPharmacotherapy201333998499923744749
   PubMed Web of Science ®Google Scholar
• International Diabetes FederationGlobal Guideline for Managing Older People with Type 2 DiabetesBrussels, BelgiumInternational Diabetes Federation2013 Available from: http://www.idf.org/sites/default/files/IDF-Guideline-for-older-people-T2D.pdfAccessed April 2, 2014
   Google Scholar
• National Institute for Health and Care ExcellenceDapagliflozin in combination therapy for treating type 2 diabetesManchester, UKNational Institute for Health and Care Excellence2013 Available from: http://www.nice.org.uk/nicemedia/live/14193/64270/64270.pdfAccessed April 2, 2014
   Google Scholar
• InagakiNKondoKYoshinariTMaruyamaNSusutaYKukiHEfficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12 week studyDiabetes Obes Metab201315121136114523782594
   PubMed Web of Science ®Google Scholar
• RosenstockJAggarwalNPolidoriDDose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetesDiabetes Care20123561232123822492586
   PubMed Web of Science ®Google Scholar